--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
3-month report


Heidelberg (euro adhoc) - SYGNIS announces three months results of fiscal year
2012/2013


Heidelberg,  August  14,  2012  -  SYGNIS  Pharma  AG  (Frankfurt:  LIOK;   ISIN
DE000A1E9B74; Prime Standard) today reports its financial results for the  first
quarter of the fiscal year 2012/2013 ended June 30, 2012.

Financials


    - The net loss in the first quarter was EUR-1.2  million (EUR-1.3 million Q1
      2011/2012).
    - Total operating expenses for the first three  months  were  down  at
      EUR 1.3 million (EUR2.2 million first quarter 2011/2012).
    - Cash including marketable securities amounted to EUR3.0 million as of June
      30, 2012 (EUR4.8 million June 30, 2011).


Operational summary


    - The focus of the business operations of SYGNIS during  the  first  quarter
      was on the preparation of the planned business  combination  of  GENETRIX'
      subsidiary X-Pol Biotech and SYGNIS. On 18 July 2012, SYGNIS and  GENETRIX
      have signed a binding Term Sheet under  which  the  companies  propose  to
      combine X-Pol Biotech - a company focussed on DNA sequencing - and SYGNIS.
      Furthermore SYGNIS has signed ahead of  schedule  a  prolongation  of  the
      standby equity distribution agreement (SEDA) with YA Global Master SPV LTD
      on 31 July 2012. The binding Term Sheet and the prolongation of  SEDA  are
      subject  to   an   exemption   granted   by   BaFin   (Bundesanstalt   für
      Finanzdienstleistungsaufsicht) from the obligations pursuant to Section 35
      of the German Takeover Act (Wertpapiererwerbs-  und  Übernahmegesetz),  in
      particular to submit a mandatory tender offer to the existing shareholders
      of SYGNIS.
    - The operating expenses and the liquidity outflow during the first  quarter
      were within the expectations of the Company.
    - In the KIBRA project further milestones were reached. Initial examinations
      with regard to therapeutic peptides are very promising and the development
      of a  peptide-based  medicine  represents  another  approach  to  treating
      dementia.
    - The discussions with potential partners for KIBRA were intensified.




Outlook


    - For the upcoming months emphasis is being placed  on  securing  sufficient
      funding and  the  further  implementation  of  the  strategic  realignment
      through the proposed merger with X-Pol Biotech. With this merger  and  the
      marketing  of  existing  products  and  technologies,  SYGNIS  expects  to
      generate initial revenues.
    - For the KIBRA project SYGNIS is looking for a pharma partner. The  Company
      has therefore started a systematic partnering process and  is  in  ongoing
      discussions with potential partners for the project. However,  should  the
      Company not succeed in winning a partner for KIBRA,  the  management  will
      have to reconsider the future of this project.
    - The Company's available financial assets as of 30  June  2012  secure  the
      liquidity of SYGNIS until approximately March 2013. This  estimation  does
      not include revenues that may result from potential research co-operations
      for the KIBRA project. To further finance  its  business  activities,  the
      Company will have to rely on further funding from March 2013 on.





|Key financial figures for the first quarter of fiscal year         |
|2012/2013 ended June 30, 2012 and corresponding figures (IFRS)     |
|Numbers in million euros          |Q1 2012/2013    |Q1 2011/2012    |
|Revenues                          |0.1             |0.0             |
|Total expenses                    |1.3             |2.2             |
|EBIT                              |-1.3            |-2.1            |
|Net results for the period        |-1.2            |-1.3            |
|Intangible assets                 |2.2             |20.6            |
|Liquidity at end of quarter       |3.0             |4.8             |
|Equity                            |4.6             |15.6            |
|(equity ratio in %)               |(65)            |(52)            |
|Long-term financial liabilities   |0.0             |8.0             |
|Operating Cash Flow               |-1.3            |-2.0            |

The report on the first quarter which ended on June 30,  2012  is  available  at
the SYGNIS webpage at www.sygnis.de.


For further information please contact:

|
Peter  Willinger                                                                
                         
|Chief Financial Officer                                                        
                                                                  |
|SYGNIS Pharma AG                                                               
                                                                  |
|Tel.: +49 6221 454 836                                                         
                                                                  |
|E-mail:  peter.willinger@sygnis.de                                              
                                                                  |



About SYGNIS Pharma
SYGNIS  Pharma  AG  (Heidelberg,  Germany)  is  currently   a   specialty   drug
development company, focusing on innovative  treatments  for  underserved  human
diseases. Early in 2012 the company decided to discontinue  its  Phase  II  lead
program AX200 in stroke. While the company continued research activities in  the
field of cognitive disorders, it started at  the  same  time  a  systematic  M&A
process, to add new operational assets  and  activities  to  SYGNIS  Pharma  AG.
SYGNIS Pharma AG is  listed  in  the  Prime  Standard  of  the  Frankfurt  Stock

Exchange under the ticker: LIOK; and ISIN: DE000A1E9B74.





### Disclaimer
Some statements included in this  press  release,  relating  neither  to  proven
financial results nor other  historical  data,  should  be  viewed  as  forward-
looking, i.e. not definite. Such statements are  mainly  predictions  of  future
results, trends, plans or goals. These statements should not  be  considered  to
be total guarantees since given their very nature they are subject to known  and
unknown risks and imponderability and can be affected  by  other  factors  as  a
consequence of which the actual results, plans and goals  of  SYGNIS  Pharma  AG
may deviate greatly from the  established  conclusions  or  implied  predictions
contained in such statements. SYGNIS does not undertake to  publicly  update  or
revise these statements in the light of new information  or  future  results  or
for any other reason. ###


Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail:  Michael.Wolf@sygnis.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
mail:         contact@sygnis.de
WWW:         http://www.sygnis.de
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             Stuttgart, regulated dealing/prime standard: Frankfurt 
language:   English